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Primary tumours of the heart have an incidence of only
0.001–0.28% (McAllister and Fenoglio, 1978). Of these, approxi-
mately 25% are sarcomas occurring in adults (Silverman, 1980).
Angiosarcomas and rhabdomyosarcomas are the most frequent
histological subtypes (Putnam et al, 1991). In general, the survival
of these patients is short (Molina et al, 1990; Putnam et al, 1991;
Burke et al, 1992) despite complete surgical resection by heart
transplantation (Crespo et al, 1993).
The molecular characterization of primary cardiac sarcomas
with respect to genetic alterations in p53 and K-ras genes has not
been widely studies. However, there is some evidence of the pres-
ence of p53 and K-ras gene alterations in sarcomas located in
other organs (Muligan et al, 1990). A number of reports dealing
with the occurrence of p53 gene mutations in sarcomas show it to
be a frequent event, especially in the rhabdomyosarcoma histo-
logic subtype (Felix et al, 1992; Wurl et al, 1996; Kusufuka et al,
1997). Specifically, Naka et al (1997) reported two cases of p53
gene mutations in four patients with primary cardiac angio-
sarcomas.
Different mutation rates of ras genes have been detected in
sarcomas. K-ras mutations in 26% of hepatic angiosarcomas
(Przygodzki et al, 1997), point H-ras mutations in 33% of rhabdo-
myosarcomas and malignant fibrous histiocytomas (Wilke et al,
1993), and N-ras and K-ras mutations in 35% of rhabdomyo-
sarcomas (Stratton et al, 1989). However, genetic studies of heart
sarcomas have not been reported.
We investigated the mutational status of p53 and K-ras genes in
primary cardiac sarcomas in a small number of patients.
MATERIALS AND METHODS
Tumour samples and DNA extraction
We obtained tumour specimens from seven patients in two Madrid
hospitals. Five samples corresponded to sarcomas (three angiosar-
comas and two rhabdomyosarcomas) with two additional samples
corresponding to rhabdomyomas being taken from infants who
died of multiple cardiac rhabdomyomas 3 and 7 days after birth.
All the histological specimens were fixed in 10% formalin and
routinely processed by paraffin-embedding. Histologic confirma-
tion of the diagnosis was performed prior to the molecular study.
DNA was extracted from formalin-fixed, paraffin-embedded
tissues using chelating resin. Paraffin blocks without samples were
used as negative controls for each polymerase chain reaction
(PCR) analysis throughout the procedure.
Mutational study of the p53 gene
To establish the presence of point mutations in the conserved
exons of TP53, polymerase chain reaction/single-strand conforma-
tion polymorphism (PCR-SSCP) analysis was performed. Exons
5, 6, 7 and 8 of the p53 gene were amplified. PCR was performed
under standard conditions in a 25-ml volume containing 2-ml
(100 ng) tumour DNA template; 2.5-ml of 10 ´ PCR buffer and 1.5
U of Ampli Taq Gold (Perkin-Elmer, Roche Molecular Systems
Inc., Branchburg, NJ, USA); 200 mM deoxynucleotide triphos-
phate (dNTP) mix; 0.6 mM of each primer; and various concentra-
tions of magnesium chloride (MgCl2) depending on the primer and
distilled water (H2O) needed to reach the total volume. For PCR
amplification, the samples underwent 40 cycles at 94°C for 1 min,
followed by subjection to different annealing temperatures
depending on the primer, and 70°C for 1 min. The amplified prod-
ucts were denatured by mixing with 15 ml of denaturing stop solu-
tion that contained 98% formamide, 10 ml l–1 edathamil (pH 8.0),
0.02% xylene cyanol and 0.02% bromophenol blue, being heated
to 95°C for 5 min and rapidly cooled on ice. Electrophoresis was
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250 V. The allelic band intensity on the gels was detected by non-
radioisotopic means using a commercially available silver staining
method (Oto et al, 1993). All specimens that showed a differential
band at SSCP were amplified to obtain templates for DNA
sequencing. These amplifications were independent to those used
for SSCP analysis. Amplified DNA fragments were purified from
0.9% agarose gels using the Geneclean Kit (Bio-101, Inc., La
Jolla, CA, USA) and used for direct DNA sequencing by the
ddNTP method with the Sequenase Kit (United States
Biochemical Corp. Cleveland, OH, USA).
Mutational analysis of K-ras gene
PCR amplification of K-ras gene, using 100 ng genomic DNA as
template, was carried out in a 25-ml reaction volume with a final
concentration of 1 ´ PCR buffer and 1.5 units of Ampli Taq DNA
polymerase (Perkin-Elmer, Roche Molecular Systems Inc.,
Branchburg, NJ, USA); 200 mM dNTP mix; 0.6 mM of each primer;
2.5 mM MgCl2 and distilled H2O to reach the total volumes. For
amplification, each sample was denatured at 94°C for 5 min and
subjected to 35 cycles (94°C for 30 s, 58°C for 40 s and 72°C for
30 s, followed by a final 7-min extension at 72°C). The amplified
products were mixed with 20 ml denaturing stop solution that
contained 98% formamide, 10 mml l–1 edathamil (pH 8.0), 0.02%
xylene cyanol and 0.02% bromophenol blue, heated to 95°C
for 5 min and rapidly cooled on ice. The samples were elec-
trophoresed on non-denaturing 12% polyacrylamide gels at 250 V
overnight at room temperature. Products were visualized by non-
radioisotopic means using a commercially available silver staining
method (Oto et al, 1993). Primers used for amplification of exon 1
of K-ras, which contains codons 12 and 13, were: 5¢-GACT-
GAATATAAACTTGTGGTAGT and 5¢-CTATTGTTGGATCAT-
ATTCGTCC. All specimens, with and without differential bands
at SSCP, were sequenced following the same method as used in the
sequencing process of p53 gene.
RESULTS
The clinicopathologic characteristics of the patients and treatments
administered are listed in Table 1.
The five cardiac sarcomas were screened for mutations by PCR-
SSCP and direct sequencing at exons 5, 6, 7 and 8 of the p53 gene
and exon 1 of the K-ras gene. SSCP analysis of the exons of the
p53 gene did not reveal any cases of bands with altered
electrophoretic mobility. Considering that SSCP sensitivity is
low under certain circumstances (Hayashi, 1991) direct sequence
analysis for exons 5, 6, 7 and 8 of the p53 gene in each case were
performed and no point mutations were detected. The first exon of
K-ras was checked by SSCP in all lesions and three sarcomas
showed a mobility shift; however, to avoid false-negatives, direct
sequence analysis was performed in all cases. Mutations at codon
13 of K-ras were present in all three cases that displayed changes
in mobility. G to A transition at the first base of codon 13, which
resulted in one amino acid substitution (Gly-13 to Ser) (Figure 1),
was detected in two angiosarcomas and one rhabdomyosarcoma.
Although our series does not permit a statistical study due to its
small size, in terms of clinicopathologic features, the three patients
with K-ras mutations were under 50 years of age (mean 31 years)
and the two patients without K-ras mutations were over 50.
Moreover, it is noteworthy that the same K-ras mutation was
present in both rhabdomyosarcoma and angiosarcoma.
DISCUSSION
The rare occurrence of primary cardiac sarcomas may explain the
almost complete absence of molecular studies involving the mole-
cular status of p53 and K-ras genes in these tumours. To the best of
our knowledge, there have been no reports dealing with mutations
in the ras gene family, and there is only one report of a study
examining p53 gene mutations in cardiac angiosarcomas with
point mutations being found in 50% of cases (Naka et al, 1997).
No point mutations in the p53 gene were detected in the cases we
present here, suggesting that it is difficult to draw conclusions
about p53 inactivation in these rare tumours from small series.
However, the current study shows that K-ras gene mutations
could be relatively frequent in these rare tumours. Of the five cases
studied, we found a mutation at the first position of codon 13
(Gly-13 to Ser) in three sarcomas, two angiosarcomas and one
rhabdomyosarcoma, while no mutations were observed in the two
cardiac rhabdomyomas assessed. Although the implication of the
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Table 1 Molecular and clinicopathologic patients characteristics
Age Sex Histology Chamber Treatment Postsurg. Survival Status p53 gene K-ras
ChT (months) Mut Mut
54 F Angio RA No specific No 5 D No No
27 M Rhabdo LA Resection ADM 7 D No Yes
31 M Angio RA Transpl ADM 10 D No Yes
36 M Angio RA Transpl ADM 8 D No Yes
52 F Rhabdo LV Transpl ADM 45 D No No
F, female; M, male; Angio, angiosarcoma; Rhabdo, rhabdomyosarcoma; RA, right atrium, LA, left atrium: LV, left ventricle; Transpl, heart transplantation;
D, dead; Mut, mutations; ADM, doxorubicin; ChT, chemotherapy.
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Figure 1 Sequencing analysis of patients P2, P3 and P4 shows a
nucleotide change (C to T) in the reverse sequence that corresponds to a
transition (G to A) of the K-ras gene. This transition at codon 13 causes an
amino acid change (Gly-Ser). The change was not observed in the DNA of
the control case (C)ras oncogene family in the development of mesenchymal tumours
was reported long ago (Stratton et al, 1989) there were no studies
available concerning the presence of these point mutations in
sarcomas derived from heart tissue.
As was mentioned above, the clinicopathologic features of our
patients were similar to those reported elsewhere with respect to
age, tumour location and histological type. In our series, it is inter-
esting to note that the same mutation was observed in both a heart
rhabdomyosarcoma and an angiosarcoma.
In conclusion, we report a small series of heart sarcomas
subjected to a specific molecular study that shows the presence
of K-ras mutations at codon 13. Nevertheless, there were no
differential clinical characteristics except for the patients
harbouring these mutations being younger and predilection for
the male sex.
ACKNOWLEDGEMENTS
We are indebted to Mrs M Messman and Mr M Hadley-Adams for
the revision and preparation of the manuscript. This work was
supported by grants from the Fundación Caja Madrid and Bristol-
Myers, S.A.
REFERENCES
Burke AP, Cowan D and Virmani R (1992) Primary sarcomas of the heart. Cancer
69: 387–395
Crespo MG, Pulpon LA, Pradas G, Serrano S, Segovia J, Vegazo I, Salas C, España
P, Silva L and Burgos R (1993) Heart transplantation for cardiac
angiosarcoma: should its indication be questioned? J Heart Lung Transplant
12: 527–530
Felix CA, Kappel CC, Mitsudomi T, Nau MM, Tsokos M, Crouch GD, Nisen PD,
Winick NJ and Helman LJ (1992) Frequency and diversity of p53 mutations in
childhood rhabdomyosarcoma. Cancer Res 52: 2243–2247
Hayashi K (1991) PCR-SSCP: a simple and sensitive method for detection of
mutations in the genomic DNA. PCR Methods Appl 1: 34–38
Kusafuka T, Fukuzawa M, Oue T, Komoto Y, Yoneda A and Okada A (1997)
Mutation analysis of p53 gene in childhood malignant solid tumors. J Pediatr
Surg 32: 1175–1180
McAllister HA and Fenoglio JJ (1978) Tumors of the cardiovascular system. In:
Atlas of Tumor Pathology, vol. 15, pp. 73–119. Washington DC: Armed Forces
Institute of Pathology
Molina JE, Edwards JE and Ward HB (1990) Primary cardiac tumors: experience at
the University of Minnesota. J Thorac Cardiovasc Surg 38: 183–191
Mulligan LM, Matlashewski GJ, Scrable HJ and Cavenee WK (1990) Mechanism of
p53 loss in human sarcomas. Proc Natl Acad Sci USA 87: 5863–5867
Naka M, Tomita Y, Nakanishi H, Araki N, Hongyo T, Ochi T and Aozasa K (1997)
Mutations of p53 tumor-suppressor gene in angiosarcoma. Int J Cancer 71:
952–955
Oto M, Miyake S and Yuasa Y (1993) Optimization of nonradioisotopic single
strand conformation polymorphism analysis with a conventional minislab gel
electrophoresis apparatus. Anal Biochem 213: 19–22
Przygodzki RM, Finkelstein SD, Keohavong P, Zhu D, Bakker A, Swalsky PA, Soini
Y, Ishak KG and Bennett WP (1997) Sporadic and thorotrast-induced
angiosarcomas of the liver manifest frequent and multiple point mutations in
K-ras-2. Lab Invest 76: 153–159
Putnam JB, Sweeney MS, Colon R, Lanza LA, Frazier OH and Cooley D (1991)
Primary cardiac sarcomas. Ann Thorac Surg 51: 906–910
Silverman NA (1980) Primary cardiac tumors. Ann Surg 191: 127–138
Stratton MR, Fisher C, Gusterson BA and Cooper CS (1989) Detection of point
mutations in N-ras and K-ras genes of human embryonal rhabdomyosarcomas
using oligonucleotide probes and the polymerase chain reaction. Cancer Res
49: 6324–6327
Wilke W, Maillet M and Robinson R (1993) H-ras-1 point mutations in soft tissue
sarcomas. Mod Pathol 6: 129–132
Wurl P, Taubert H, Bache M, Kroll J, Meye A, Berger D, Siermann A, Holzhausen
HJ, Hinze R, Schmidt H and Rath FW (1996) Frequent occurrence of p53
mutations in rhabdomyosarcoma and leiomyosarcoma, but not in fibrosarcoma
and malignant neural tumors. Int J Cancer 69: 317–323
K-ras mutations in heart sarcomas 1185
British Journal of Cancer (2000) 82(6), 1183–1185 © 2000 Cancer Research Campaign